{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:55:50Z","timestamp":1766732150395,"version":"3.48.0"},"reference-count":27,"publisher":"Galenos Yayinevi","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"DOI":"10.4274\/tjo.galenos.2025.34783","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T11:00:00Z","timestamp":1766660400000},"page":"299-304","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization"],"prefix":"10.4274","volume":"55","author":[{"given":"Arma\u011fan","family":"\u00d6zg\u00fcr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nil\u00fcfer","family":"Ye\u015fil\u0131rmak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Arda","family":"\u0130nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emin \u00dcmit","family":"Ba\u011fr\u0131a\u00e7\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet C\u00fcneyt","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","unstructured":"1. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415-429.","journal-title":"Surv Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","unstructured":"2. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.","journal-title":"Curr Opin Ophthalmol"},{"key":"ref2","unstructured":"3. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996;37:1625-1632."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s004170050106","article-title":"Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor","volume":"236","author":"Kruse","year":"1998","unstructured":"4. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, V\u00f6lcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 1998;236:461-466.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bjo.87.1.101","article-title":"Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation","volume":"87","author":"Cursiefen","year":"2003","unstructured":"5. Cursiefen C, Hofmann-Rummelt C, K\u00fcchle M, Schl\u00f6tzer-Schrehardt U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol. 2003;87:101-106.","journal-title":"Br J Ophthalmol"},{"key":"ref5","unstructured":"6. Phillips GD, Stone AM, Jones BD, Schultz JC, Whitehead RA, Knighton DR. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 1994;8:961-965."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","article-title":"Current and emerging therapies for corneal neovascularization","volume":"16","author":"Roshandel","year":"2018","unstructured":"7. Roshandel D, Eslani M, Baradaran-Rafii A, Cheung AY, Kurji K, Jabbehdari S, Maiz A, Jalali S, Djalilian AR, Holland EJ. Current and emerging therapies for corneal neovascularization. Ocul Surf. 2018;16:398-414.","journal-title":"Ocul Surf"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajo.2012.06.007","article-title":"Short-term topical bevacizumab in the treatment of stable corneal neovascularization","volume":"154","author":"Cheng","year":"2012","unstructured":"8. Cheng SF, Dastjerdi MH, Ferrari G, Okanobo A, Bower KS, Ryan DS, Amparo F, Stevenson W, Hamrah P, Nallasamy N, Dana R. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol. 2012;154:940-948.","journal-title":"Am J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/imj.14033","article-title":"Biosimilars are coming: ready or not","volume":"48","author":"Zalcberg","year":"2018","unstructured":"9. Zalcberg J. Biosimilars are coming: ready or not. Intern Med J. 2018;48:1027-1034.","journal-title":"Intern Med J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1158\/1078-0432.CCR-18-0566","article-title":"FDA's approval of the first biosimilar to bevacizumab","volume":"24","author":"Casak","year":"2018","unstructured":"10. Casak SJ, Lemery SJ, Chung J, Fuchs C, Schrieber SJ, Chow ECY, Yuan W, Rodriguez L, Gwise T, Rowzee A, Lim S, Keegan P, McKee AE, Pazdur R. FDA's approval of the first biosimilar to bevacizumab. Clin Cancer Res. 2018;24:4365-4370.","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Bagriacik UE, Yaman M, Oruklu N. Development and characterization of monoclonal antibodies specific for human vascular endothelial growth factor [conference abstract]. J Biotechnol. 2017;256 Supplement:S31-S32.","DOI":"10.1016\/j.jbiotec.2017.06.656"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/IAE.0b013e31826f0675","article-title":"Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center","volume":"33","author":"Falavarjani","year":"2013","unstructured":"12. Falavarjani KG, Modarres M, Hashemi M, Parvaresh MM, Naseripour M, Zare-Moghaddam A, Nekoozadeh S. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina. 2013;33:971-974.","journal-title":"Retina"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ajo.2011.11.035","article-title":"An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab","volume":"153","author":"Goldberg","year":"2012","unstructured":"13. Goldberg RA, Flynn HW Jr, Isom RF, Miller D, Gonzalez S. An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153:204-208.","journal-title":"Am J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ajo.2011.11.023","article-title":"Avastin doesn't blind people, people blind people","volume":"153","author":"Gonzalez","year":"2012","unstructured":"14. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol. 2012;153:196-203.","journal-title":"Am J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1097\/00007890-199812150-00016","article-title":"Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat","volume":"66","author":"Yatoh","year":"1998","unstructured":"15. Yatoh S, Kawakami Y, Imai M, Kozawa T, Segawa T, Suzuki H, Yamashita K, Okuda Y. Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. Transplantation. 1998;66:1519-1524.","journal-title":"Transplantation"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/00007890-198503000-00004","article-title":"A comparison of the effects of topical cyclosporine and topical steroid on rabbit corneal allograft rejection","volume":"39","author":"Williams","year":"1985","unstructured":"16. Williams KA, Grutzmacher RD, Roussel TJ, Coster DJ. A comparison of the effects of topical cyclosporine and topical steroid on rabbit corneal allograft rejection. Transplantation. 1985;39:242-244.","journal-title":"Transplantation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08820530902800017","article-title":"Review of the ocular angiogenesis animal models","volume":"24","author":"Montezuma","year":"2009","unstructured":"17. Montezuma SR, Vavvas D, Miller JW. Review of the ocular angiogenesis animal models. Semin Ophthalmol. 2009;24:52-61.","journal-title":"Semin Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1167\/iovs.09-4571","article-title":"The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency","volume":"51","author":"Lin","year":"2010","unstructured":"18. Lin CT, Hu FR, Kuo KT, Chen YM, Chu HS, Lin YH, Chen WL. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci. 2010;51:6277-6285.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref18","unstructured":"19. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41:2148-2153."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10792-013-9732-8","article-title":"The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization","volume":"33","author":"Acar","year":"2013","unstructured":"20. Acar BT, Halili E, Acar S. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Int Ophthalmol. 2013;33:507-513.","journal-title":"Int Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000224783","article-title":"Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats","volume":"42","author":"Hashemian","year":"2009","unstructured":"21. Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res. 2009;42:90-95.","journal-title":"Ophthalmic Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","unstructured":"22. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50:4807-4813.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1615\/CritRevImmunol.v18.i4.20","article-title":"The immunology of corneal graft rejection","volume":"18","author":"Rocha","year":"1998","unstructured":"23. Rocha G, Desch\u00eanes J, Rowsey JJ. The immunology of corneal graft rejection. Crit Rev Immunol. 1998;18:305-325.","journal-title":"Crit Rev Immunol"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992;110:1392-1403.","DOI":"10.1001\/archopht.1992.01080220054021"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00417-014-2851-8","article-title":"Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab","volume":"253","author":"Dekaris","year":"2015","unstructured":"25. Dekaris I, Gabri\u0107 N, Dra\u010da N, Pauk-Guli\u0107 M, Mili\u010di\u0107 N. Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2015;253:287-294.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1083\/jcb.200409115","article-title":"Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors","volume":"169","author":"Lee","year":"2005","unstructured":"26. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005;169:681-691.","journal-title":"J Cell Biol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"8454","DOI":"10.1128\/MCB.00821-07","article-title":"Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)\/heparin affin regulatory peptide (pleiotrophin) and VEGF\/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis","volume":"27","author":"Dean","year":"2007","unstructured":"27. Dean RA, Butler GS, Hamma-Kourbali Y, Delb\u00e9 J, Brigstock DR, Courty J, Overall CM. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)\/heparin affin regulatory peptide (pleiotrophin) and VEGF\/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol. 2007;27:8454-8465.","journal-title":"Mol Cell Biol"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:53:55Z","timestamp":1766732035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oftalmoloji.org\/articles\/evaluation-of-a-new-potential-bevacizumab-biosimilar-in-corneal-neovascularization\/doi\/tjo.galenos.2025.34783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12,25]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2025.34783","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"type":"print","value":"1300-0659"},{"type":"electronic","value":"2147-2661"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}